| CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy |
19 |
| The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia |
17 |
| Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia |
15 |
| Recently approved therapies in acute myeloid leukemia: A complex treatment landscape |
15 |
| Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study |
11 |
| Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study |
10 |
| 8q24/&ITMYC&IT rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms |
10 |
| Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms |
10 |
| Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology |
9 |
| Extracellular vesicles in leukemia |
9 |
| CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia |
8 |
| Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib |
8 |
| Interpretation of clinical endpoints in trials of acute myeloid leukemia |
8 |
| A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia |
7 |
| Prognostic significance of SOX SOX SOX SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia |
7 |
| PD-1/PD-L1 checkpoint in hematological malignancies |
7 |
| Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC) |
7 |
| The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia |
7 |
| A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease |
7 |
| MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations |
7 |
| Over expression of circulating miR-155 predicts prognosis in diffuse large B-cell lymphoma |
6 |
| Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma |
6 |
| Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation |
6 |
| Retrospective analysis of 36 fusion genes in 2479 Chinese patients of de novo acute lymphoblastic leukemia |
6 |
| Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study |
6 |
| Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia &ITin vivo&IT/&ITin vitro&IT |
6 |
| Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies |
6 |
| Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia |
6 |
| Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML) |
6 |
| Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS |
6 |
| Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience |
6 |
| Comparative study of porcine anti-human lymphocyte immunoglobulin and rabbit anti-human thymocyte immunoglobulin as a first-line treatment of acquired severe aplastic anemia |
6 |
| Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan |
6 |
| Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway |
6 |
| Incidence and survival of therapy related myeloid neoplasm in United States |
6 |
| Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia |
5 |
| Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms |
5 |
| Management of melanoma in patients with chronic lymphocytic leukemia |
5 |
| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
5 |
| Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP |
5 |
| Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China? |
5 |
| Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events |
5 |
| Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay |
5 |
| Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses |
5 |
| Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon |
5 |
| Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway |
5 |
| Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia |
5 |
| Incorporating newer agents in the treatment of acute myeloid leukemia |
4 |
| Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection |
4 |
| Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma |
4 |
